The muscarinic M4 receptor is the functionally predominant subtype in rat and mouse striatum as demonstrated using [35S] GTPγS binding

European Journal of Pharmacology

Volumn 652, Issue 1-3, 2011, Pages 1-6

  Chapman, Kathryn L ^a   Vaswani, Dina ^a   Hendry, Nicola ^a   Langmead, Christopher J ^a   Kew, James N C ^a   Watson, Jeannette M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

GTP S binding assay; Knock out mouse; Muscarinic 4 receptor; Native tissue; Rat striatum

Indexed keywords

ACETYLCHOLINE; ARECOLINE; CARBACHOL; CLOZAPINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MILAMELINE; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; OXOTREMORINE M; SULFUR 35; XANOMELINE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; DRUG RECEPTOR BINDING; KNOCKOUT MOUSE; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALS; CELL MEMBRANE; CORPUS STRIATUM; CRICETINAE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MALE; MICE; MICE, KNOCKOUT; MUSCARINIC ANTAGONISTS; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RECEPTOR, MUSCARINIC M4; RECEPTORS, MUSCARINIC; SULFUR RADIOISOTOPES;

EID: 78650886586     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.079     Document Type: Article

References (24)

1. Bohme T.M., C.E. ugelli-Szafran, Hallak H., Pugsley T., Serpa K., and Schwarz R.D. Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors J. Med. Chem. 45 2002 3094 3102
2. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
3. A.E. Brady, C.K. Jones, T.M. Bridges, J.P. Kennedy, A.D. Thompson, J.U. Heiman, M.L. Breininger, P.R. Gentry, H. Yin, S.B. Jadhav, J.K. Shirey, P.J. Conn, and C.W. Lindsley Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats J. Pharmacol. Exp. Ther. 327 2008 941 953
4. F.P. Bymaster, H.E. Shannon, K. Rasmussen, N.W. DeLapp, J.S. Ward, D.O. Calligaro, C.H. Mitch, C. Whitesitt, T.S. Ludvigsen, M. Sheardown, M. Swedberg, T. Rasmussen, P.H. Olesen, L. Jeppesen, P. Sauerberg, and A. Fink-Jensen Potential role of muscarinic receptors in schizophrenia Life Sci. 64 1999 527 534
5. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
6. Fruchart-Gaillard C., Gilquin B., S. ntil-Delbeke, Le N.N., Tamiya T., Corringer P.J., Changeux J.P., Menez A., and Servent D. Experimentally based model of a complex between a snake toxin and the alpha 7 nicotinic receptor Proc. Natl Acad. Sci. USA 99 2002 3216 3221
7. C.J. Langmead, J. Watson, and C. Reavill Muscarinic acetylcholine receptors as CNS drug targets Pharmacol. Ther. 117 2008 232 243
8. K. Leach, R.E. Loiacono, C.C. Felder, D.L. McKinzie, A. Mogg, D.B. Shaw, P.M. Sexton, and A. Christopoulos Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties Neuropsychopharmacology 35 2010 855 869
9. Leff P., and Dougall I.G. Further concerns over Cheng-Prusoff analysis Trends Pharmacol. Sci. 15 1993 141 144
10. C. Liu, I. Chu, and S. Hwang Factorial designs combined with the steepest ascent method to optimize serum-free media for CHO cells Enzyme Microb. Technol. 28 2001 314 321
11. N.R. Mirza, D. Peters, and R.G. Sparks Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists CNS Drug Rev. 9 2003 159 186
12. C.P. Nelson, and R.A. Challiss "Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology Biochem. Pharmacol. 73 2007 737 751
13. M.C. Olianas, A. Adem, E. Karlsson, and P. Onali Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective M4 ligand muscarinic toxin 3 (MT3) Br. J. Pharmacol. 118 1996 283 288
14. R. Rodríguez-Puertas, J. Pascual, T. Vilaró, and V. Pazos Autoradiographic distribution of M1. M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease Synapse 26 1997 341 350
15. H. Salah-Uddin, D.R. Thomas, C.H. Davies, J.J. Hagan, M.D. Wood, J.M. Watson, and R.A. Challiss Pharmacological assessment of M1 muscarinic acetylcholine receptor-Gq/11 protein coupling in membranes prepared from postmortem human brain tissue J. Pharmacol. Exp. Ther. 325 2008 869 874
16. A. Shekhar, W.Z. Potter, J. Lightfoot, J. Lienemann, S. Dube, C. Mallinckrodt, F.P. Bymaster, D.L. McKinzie, and C.C. Felder Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia Am. J. Psychiatry 165 2008 1033 1039
17. T.A. Spalding, C. Trotter, N. Skjaerbaek, T.L. Messier, E.A. Currier, E.S. Burstein, D. Li, U. Hacksell, and M.R. Brann Discovery of an ectopic activation site on the M(1) muscarinic receptor Mol. Pharmacol. 61 2002 1297 1302
18. E.T. Tzavara, F.P. Bymaster, R.J. Davis, M.R. Wade, K.W. Perry, J. Wess, D.L. McKinzie, C. Felder, and G.G. Nomikos M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies FASEB J. 18 2004 1410 1412
19. Vilaró M.T., Mengod G., Palacios G., and Palacios J.M. Receptor distribution in the human and animal hippocampus: focus on muscarinic acetylcholine receptors Hippocampus 3 1993 Spec No, 149-56.
20. M. Waelbroeck, M. Tastenoy, J. Camus, and J. Christophe Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain Mol. Pharmacol. 38 1990 267 273
21. J. Watson, L. Collin, M. Ho, G. Riley, C. Scott, J.V. Selkirk, and G.W. Price 5-HT(1A) receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems Br. J. Pharmacol. 130 2000 1108 1114
22. M.D. Wood, K.L. Murkitt, M. Ho, J.M. Watson, F. Brown, A.J. Hunter, and D.N. Middlemiss Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes HM1, HM2, HM3, HM4 and HM5 using microphysiometry Br. J. Pharmacol. 126 1999 1620 1624
23. M.L. Woolley, H.J. Carter, J.E. Gartlon, J.M. Watson, and L.A. Dawson Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice Eur. J. Pharmacol. 603 2009 147 149
24. R.P. Yasuda, W. Ciesla, L.R. Flores, S.J. Wall, M. Li, S.A. Satkus, J.S. Weisstein, B.V. Spagnola, and B.B. Wolfe Development of antisera selective for M4 and M5 muscarinic cholinergic receptors: distribution of M4 and M5 receptors in rat brain Mol. Pharmacol. 43 1993 149 157